Introduction

The Coronavirus Disease 2019 (COVID-19) outbreak represents a serious public health problem that is straining health systems around the world. As of June 25th, 2020, as many as 9,296,202 cases of COVID-19 have been confirmed and 479,133 patients have died globally, according to the World Health Organization (WHO) [1]. In addition to confirmed cases, there are also suspected cases of COVID-19 which should be promptly tested where possible in order to immediately implement isolation measures and trace contacts. In a context of uncertainty, since the infection is caused by a new and still little understood virus for which no vaccines or specific medications are currently available, the recognition of clinical signs and symptoms as well as clinical features in affected subjects is of vital importance. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the latest known virus that has spread worldwide.

In addition to confirmed cases, there are also suspected cases of COVID-19 which should be promptly tested where possible in order to immediately implement isolation measures and trace contacts. In a context of uncertainty, since the infection is caused by a new and still little understood virus for which no vaccines or specific medications are currently available, the recognition of clinical signs and symptoms as well as clinical features in affected subjects is of vital importance. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the latest known virus that has spread worldwide. Viruses, particularly RNA viruses, have high mutation rates and are characterized by a particularly high virulence and transmissibility and can cause more or less severe infections. To date, SARS-CoV-2 appears to be highly virulent and easily transmissible, it can affect many organs of the body and manifest in many ways [2]. Applying the lessons learned from past epidemics can help us to better address the new challenges. The previous Coronavirus (CoV) epidemic that hit the world population was Severe Acute Respiratory Syndrome (SARS) in 2003 which manifested as an atypical pneumonia with reported symptoms including fever, dry cough, dyspnea, diarrhea and sore throat [3]. The modes of transmission and the clinical features of the two infections initially seemed to be superimposable. Both infections are transmitted through respiratory droplets or secretions and by close person-to-person contact [4]. In some cases, COVID-19 patients do not show the typical signs of respiratory infections but have unusual symptoms or only very mild symptoms [5]. Furthermore, the presence of underlying health conditions increases the risk of developing severe illness [6]. Therefore, early recognition of suspected cases through the evaluation of clinical and symptomatic characteristics should represent the first tool that can direct towards an early identification of the infection, a suitable diagnostic procedure and the adoption of appropriate containment measures.
Virological characteristics

This century has been characterized by the presence of several zoonotic coronavirus epidemics spread from southern China, which have infected humans as a result of genetic recombination that have allowed to make the leap to a new species [7]. Phylogenetic analysis revealed that SARS-CoV-2, like Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), belongs to the genus *Betacoronavirus* of the *Coronaviridae* family, exhibiting about 79% sequence identity with SARS-CoV and sharing the same receptor-binding domain (RBD) structure [8]. The complete genome sequence contains 29,751 bp for SARS-CoV [9] and 29,811 bp for SARS-CoV-2 [10]. The mutation rate in the SARS-CoV genome is similar to that of other coronaviruses and moderate compared to other RNA viruses [11], unlike that of SARS-CoV-2 which appears to have a higher evolutionary rate estimated (mean $2.15 \times 10^{-6}$ subs/site/day corresponding to $7.8 \times 10^{-4}$ subs/site/year) (Tab. I) [12].

Epidemiological characteristics

The first cases of atypical pneumonia of unknown etiology of SARS were reported on November 16th, 2002 in Guangdong Province, China and then spread mainly among household contacts and healthcare workers [13]. It was only after 300 people became infected and 5 died, on February 11th, 2003, that the Chinese Ministry of Health informed the WHO of an outbreak of acute respiratory syndrome [14]. At the end of February 2003, the infection was transmitted to Hong Kong by an infected doctor and in a few months the infection spread to other countries of the world mainly through intercontinental flights. The epidemic spread rapidly to Hong Kong, Taiwan, Singapore and Hanoi, mostly related to the movement of people during the Chinese New Year holiday season [15]. The number of reported cases increased exponentially, prompting the WHO to issue a global alert about the disease on March 13, 2003 (Tab. I) [14].

The outbreak was contained in July 2003 with a total of 8,098 cases and 774 deaths in 32 countries, with an estimated overall case fatality rate (CFR) estimate of 9.6%. In mainland China, the country where the epidemic started and where the greatest number of cases was reported, there were 5,327 infected people and 349 deaths [16]. A number of hospitals in various regions of China were designated to treat SARS patients only. The outbreak came under control and the number of new cases gradually declined. On June 24th, 2003, Beijing was removed from the WHO’s list of areas with recent local transmission of SARS [15].

The country most affected after China was Hong Kong with 1,755 cases and a mortality rate of 17%. The most affected country outside Asia was Canada with 251 cases and 43 deaths. The European region was slightly affected, with 33 total cases and one death in France. In Italy, only 4 cases have been observed [17]. The epidemic was declared ended on July 5th, 2003 [14].

Another global epidemic is currently underway which started on December 7th, 2019, the day when the first positive COVID-19 case was detected. The first cases of pneumonia of unknown origin were found in China, connected to those who frequent the wholesale market of seafood and wet animals located in Wuhan, in the province of Hubei, assuming also in this case a zoonotic source [18]. A new coronavirus, named SARS-CoV-2, was isolated from the epithelium of these patients. It then spread, through person-to-person transmission in family homes and hospitals, outside Hubei Province in China to many countries across the world. The family of the causative agent of this outbreak as well as the country where this epidemic started are the same as those of SARS [19].

The announcement of this epidemic was provided by the Wuhan government to the WHO on January 3rd, 2020, after the involvement of 27 persons and no deaths [20]. Following a rapid spread in China and around the world, on January 30, 2020, the International Health Regulations Emergency Committee of the WHO declared the outbreak a public Health Emergency of International Concern (PHEIC) [21]. About 40 days after the declaration of the global emergency, with over 118,000 cases in 114 countries and territories worldwide and 4,291 deaths, on 11 March 2020, WHO announced the state of pandemic (Tab. I). The last time the WHO used the label was on June 11, 2009 for the H1N1 flu, known as “swine flu”, which spread across the world, whereas the 2002-2004 SARS outbreak was never declared a pandemic.

Since the end of December 2019 and as of June 25th, 2020, the infection has been detected in all countries causing more

---

**Tab. I. Summary of virological and epidemiological characteristics of SARS-CoV and SARS-CoV-2 infections.**

| Characteristics          | SARS-CoV       | SARS-CoV-2          |
|--------------------------|----------------|---------------------|
| First occurrence         | Nov 16, 2002 in Foshan, Guangdong | Dec 07, 2019 in Wuhan, Hubei |
| Global alert declaration (WHO) | March 13, 2003 | Jan 30, 2020 |
| Pandemic declaration (WHO) | - | March 11th, 2020 |
| Genome                   | RNA            | RNA                 |
| Length, bp               | 29,751         | 29,811              |
| Mutation rate RNA        | 0.80-2.38 × 10-3 subs/site/year | 7.8 × 10-4 subs/site/year |
| Mode of transmission     | Respiratory droplet | Respiratory droplet |
|                          | Contact        | Contact             |
|                          | -              | Fecal-oral (?)      |
|                          | -              | Airborne (?)        |
| Incubation period (median) | 4.0 days (95% CI: 3.6-4.4) | 5.1 days (95% CI: 4.5-5.8) |
| R0                       | 2.4            | 1.4-7.23            |
| Asymptomatic rate        | 2.3-13%        | 5-8%                |
| Case fatality rate        | 9.6%           | 5.1%                |

SARS-CoV: severe acute respiratory syndrome; SARS-CoV-2: coronavirus disease-2019; bp: base pairs; R0: basic reproduction number; CI: confidence interval.
CLINICAL FEATURES OF COVID-19 AND SARS EPIDEMICS

Transmission

Both viruses are transmitted from human to human via droplets generated by coughing and sneezing, through exposure to fomites and through direct contact of mucous membranes (eyes, nose and mouth).

Whether the infection can be transmitted by the oral or conjunctival routes has not yet been demonstrated. However, SARS-CoV2 has been detected in tears [22], similar to SARS-CoV [23]. Although there is a low prevalence of SARS-CoV-2 in the tear fluid of patients, it cannot be excluded that the infection could be transmitted via the eyes [24]. The role of fecal-oral transmission for SARS-CoV is still unknown. Although some coronaviruses known to be spread by the fecal-oral route [25], there is currently no evidence that this mode of transmission plays a key role in SARS [3]. There is still limited knowledge regarding fecal-oral transmission of SARS-CoV2, although Chen Y et al. have demonstrated the presence of SARS-CoV-2 RNA in the feces of COVID-19 patients suggesting that, in addition to respiratory and body contact, fecal-oral transmission is a potential route for SARS-CoV-2 infection [26]. In a meta-analysis, SARS-CoV-2 RNA was detected in 48.1% of the stool samples derived from a cohort of patients with COVID-19 and persisted even after respiratory samples were negative (Tab. I) [27].

In spite of the fact that the data on intrauterine vertical transmission are scarce, there is little, if any, clinical or serologic evidence suggestive of SARS-CoV and SARS-CoV-2 transmission from pregnant mothers to newborn infants [28, 29]. Contact with infected droplets on a surface can be a source of infection, too [3, 30]. Van Doremalen et al. found that SARS-CoV-2 can remain viable and infectious in aerosols for 3 hours and on surfaces up to days. The stability of this virus is similar to that of SARS-CoV [30]. This study has also shown that the virus is most stable on plastic and stainless steel with viable virus detected up to 72 hours in the absence of any intervention. Viruses lose their infectivity after exposure to common disinfectants such as Clorox, 75% ethanol and fixatives such as formaldehyde and paraformaldehyde [31, 32]. Careful attention should also be paid to asymptomatic cases whose role in viral transmission is still controversial. During the SARS epidemic, some studies reported the absence of asymptomatic cases, while, where reported, the incidence of asymptomatic cases corresponded to 13% of all SARS-positive cases [33]. The rate of asymptomatic or mild infections of COVID-19 ranges between 5 and 78% (Tab. I) [34, 35]. Asymptomatic SARS infection was associated with lower SARS antibody titers and the transmission from asymptomatic patients appeared to play no or only a minor role [33]. SARS-CoV viral load in upper respiratory tract secretions was low in the first 5 days of illness, then increased progressively and peaked early in the second week, which helped reduce more effectively the infection transmission in the first days of illness [36]. In a study, Zou L et al. showed that the viral RNA levels in people with COVID-19 appear to be higher soon after symptom onset compared with later in the illness [37], which suggests that transmission is more likely to occur at an earlier stage of infection even when symptoms are relatively mild. The high rate of asymptomatic infections is often the result of a long incubation period. The median incubation period for COVID-19 is estimated to be 5.1 days, (95% CI: 4.5 to 5.8) [38], slightly longer than for SARS-CoV (4.0 days, 95% CI: 3.6-4.4) (Tab. I) [39]. The incubation period for SARS in children and adolescents was 2-10 days, with a mean of 6.4 days (95% CI: 5.2-7.7) [39]. The average incubation period for COVID-19 in children is 6.5 days (95% CI: 4.6-8.4), with a range from 2 to 10 days [40]. The interval during which an individual with COVID-19 is infectious is still uncertain. The transmissibility of SARS was determined by a basic reproduction number (R0) of approximately 3, with values oscillating between 2 and 4, consistent with a disease spread by direct contact or larger virus-laden droplets that travel only a few meters rather than by lighter airborne particles [3, 41]. Some studies have estimated the mean R0 for COVID-19 to range from 1.4 to 3.3 (Tab. I) [2]. R0 is used when there is a dynamic infectious disease and the population is not vaccinated, and it is usually estimated on the basis of the growth rate of the number of cases. The estimated values of R0 were lower in the early phase of the epidemic. They subsequently increased during the other phases of the epidemic and then returned to the initial levels [42]. Therefore, COVID-19 can be considered as a highly transmissible disease compared with SARS. Epidemiological factors, such as the ability to recognize
the infection at an early stage, the measures of social distancing adopted, the access to public health resources can cause considerable variations of this parameter.

Pathogenesis and clinical features

SARS-CoV and SARS-CoV2 cause severe acute respiratory syndrome and appear to have the same pathogenesis. Both viruses use the angiotensin-converting enzyme 2 (ACE2) as cell receptor to gain entry into the human cells. The infection is triggered by the binding of the virus spike protein to ACE2 and causes both upper and lower respiratory tract infections [43, 44].

Based on past studies on SARS-CoV, both viruses bind to epithelial cells in the nasal cavity and start replicating. The viruses then propagate and migrate down the respiratory tract along the conducting airways, also becoming clinically manifest [45]. A study reports that SARS CoV-2 has higher affinity for binding than SARS CoV and this contributes to its more efficient infection of humans [46]. About 20% of the infected patients develop severe disease. The virus reaches the gas exchange units of the lung causing a progressive respiratory failure due to alveolar damage, resulting in apoptosis and even cell death [44, 47]. ACE2 receptors are present in the lung alveolar cells, but are also expressed in numerous other organs, in the enterocytes of the small intestine, as well as in the heart, kidney, bile duct, liver, esophagus and testicle, and in arterial and venous endothelial cells and arterial smooth muscle cells. This tissue distribution of ACE2 correlates with the sites of infection and with the pathology [43].

Signs and symptoms

SARS is characterized as a viral pneumonia with rapid respiratory deterioration [48]. COVID-19 has many clinical features similar to those of SARS but COVID-19 infection presents with a wide spectrum of severity and often with non-specific symptoms. About 80% of patients experience no signs or mild symptoms of disease, 14% have severe clinical manifestations and only 5% critical conditions. Older age and presence of comorbidities appear to be important factors associated with clinical severity of disease [4].

We analyzed the clinical characteristics reported in patients with SARS-CoV and SARS-CoV-2. A total of 17 and 75 studies regarding patients with SARS and COVID-19, respectively, were included in the analysis. Overall, 3,365 patients with SARS-CoV and 38,318 patients with SARS-CoV-2 were analyzed. The results are detailed in Table II. In the first part of the Table, signs and symptoms of 3,365 SARS patients and 23,280 COVID-19 patients were considered. This analysis revealed an overlap of some symptoms between the two infections. SARS-CoV2 infection presents a greater variety of symptoms and involves several organ systems. SARS-CoV affects a few organs and a limited number of symptoms are present in a high percentage of the infected subjects. In particular, the most common clinical manifestations were systemic [fever (87.90%), chills (53.52%), and malaise (49.18%)]. In addition, respiratory symptoms [cough (58.31%)], neurological symptoms [headache (44.40%)], and musculoskeletal and connective symptoms [myalgia (40.62%)] were detected. SARS-CoV2, on the other hand, preferentially infects the cells of the respiratory tract, but it also has high affinity for other organs. Therefore, symptomatic patients present a greater variety of symptoms affecting many organs but in a smaller number of subjects. Typical symptoms are respiratory among which cough is the most frequent (62.50%). Other frequent symptoms are: fever (58.9%), myalgia/arthritis (35.62%), headache (32.48%), shortness of breath/dyspnea (27.46%), and diarrhea (18.52%). Unlike SARS patients, COVID-19 patients have developed numerous other respiratory, neurological and gastrointestinal symptoms, and, in a limited number of subjects, symptoms involving organs such as skin and subcutaneous tissue, kidneys, cardiovascular system, liver and eyes.

Comorbidities

Seventeen studies have been included in the analysis of comorbidities and risk factors for a total of 3,365 patients with SARS-CoV.

In the 3,365 SARS patients analyzed, the most common comorbidities, present in a very low percentage of subjects, were diabetes (0.21%), cardiovascular disease (0.12%), COPD and chronic liver disease, both present in 0.09% of subjects. A total of 72 studies and 26,650 patients with COVID-19 have also been analyzed. The results showed the most prevalent comorbidities were hypertension (21.00%) and diabetes (15.37%), followed by cardiovascular disease (11.28%). The data also showed numerous COVID-19 infected subjects with hyperlipidemia (10.20%) or obesity (9.77%). Furthermore, diseases of the respiratory system such as COPD and asthma were present in 2.57 and 2.26% of patients, respectively. Chronic kidney disease was also found in 2.02% of patients.

Smoking habits have been reported in 2.75% of patients. There are numerous differences in the prevalence of comorbidities among the studies analyzed. In one recent study conducted, the authors presented the comorbidities of 5,700 patients hospitalized for COVID-19 in the New York City area. The most common comorbidities were hypertension (3,026; 56.6%), obesity (1,737; 41.7%) and diabetes (1,808; 33.8 %) [49]. The data are significantly different from those obtained in other studies from various areas of the world.

Guan WL et al. analyzed the clinical characteristics of more than 1,000 patients from mainland China. The most common comorbidities were hypertension in 15% of patients and diabetes in only 7.4% of patients. No other comorbidities were observed in over 2.5% of the COVID-19 patients analyzed [50].
| Characteristics                                      | N. of studies | SARS-CoV % (95% CI) | N. of studies | SARS-CoV-2 % (95% CI) |
|------------------------------------------------------|---------------|---------------------|---------------|-----------------------|
| Patients, n.                                         | 17            | 3,365               | 71            | 23,280                |
| Gender                                               |               |                     |               |                       |
| Male, n. (%)                                         | 17            | 1,360 (40.4)        | 67            | 6,530 (55.8)          |
| Female, n. (%)                                       | 17            | 2,005 (59.6)        | 67            | 5,179 (44.2)          |
| Age group                                            |               |                     |               |                       |
| Children (<18 ys), n. (%)                            | 4             | 92 (2.7)            | 15            | 807 (3.5)             |
| Adults/Older, n. (%)                                 | 14            | 3,273 (97.3)        | 55            | 22,374 (96.5)         |
| Systemic/General symptoms                            |               |                     |               |                       |
| Fever                                                | 17            | 87.90 (86.80-89.01) | 71            | 58.9 (58.23-59.49)    |
| Fatigue/Malaise                                      | 17            | 49.18 (47.49-50.87) | 71            | 8.91 (8.54-9.27)      |
| Chills                                               | 17            | 53.52 (51.84-55.21) | 71            | 0.96 (0.84-1.09)      |
| Influenza-like                                       | 17            | 30.61 (29.05-32.17) | 71            | -                     |
| Night sweats                                         | 17            | 11.80 (10.71-12.89) | 71            | -                     |
| Respiratory, thoracic and mediastinal symptoms       |               |                     |               |                       |
| Cough                                                | 17            | 58.31 (56.64-59.97) | 71            | 62.50 (61.87-63.12)   |
| Shortness of breath/Dyspnea                          | 17            | 26.48 (24.99-27.97) | 71            | 27.46 (26.89-28.03)   |
| Sputum production                                    | 17            | 26.54 (25.05-28.03) | 71            | 7.32 (6.69-7.65)      |
| Rhinorrhea/Runny nose                                | 17            | 2.97 (2.40-3.55)    | 71            | 4.90 (4.62-5.18)      |
| Sore throat                                          | 17            | 21.63 (20.24-23.03) | 71            | 3.69 (3.45-3.94)      |
| Acute respiratory distress                           | 17            | -                   | 71            | 0.77 (0.41-0.88)      |
| Nasal congestion/Stuffy nose                         | 17            | -                   | 71            | 0.55 (0.46-0.65)      |
| Chest pain                                           | 17            | 1.84 (1.39-2.30)    | 71            | 0.34 (0.26-0.41)      |
| Pharyngeal erythema                                  | 17            | -                   | 71            | 0.34 (0.26-0.41)      |
| Chest distress                                       | 17            | -                   | 71            | 0.31 (0.24-0.38)      |
| Haemoptysis                                          | 17            | 0.68 (0.41-0.96)    | 71            | 0.30 (0.23-0.37)      |
| Tachypnea                                            | 17            | 1.58 (1.15-2.00)    | 71            | 0.22 (0.16-0.28)      |
| Voice hoarse                                         | 17            | -                   | 71            | 0.06 (0.03-0.10)      |
| Coryza                                               | 17            | 15.75 (14.52-16.98) | 71            | 0.03 (0.01-0.05)      |
| Oropharyngeal pain                                   | 17            | -                   | 71            | 0.004 (0.00-0.01)     |
| Rhonchi                                              | 17            | 1.10 (0.75-1.45)    | 71            | -                     |
| Percussion dullness                                  | 17            | 0.21 (0.05-0.36)    | 71            | -                     |
| Pleurisy                                             | 17            | 0.09 (0.00-0.19)    | 71            | -                     |
| Wheezing                                             | 17            | 0.03 (0.00-0.09)    | 71            | -                     |
| Cardiovascular symptoms                              |               |                     |               |                       |
| Cardiac injury                                       | 17            | -                   | 71            | 0.12 (0.07-0.16)      |
| Palpitation                                          | 17            | 2.91 (2.34-3.48)    | 71            | 0.12 (0.08-0.17)      |
| Tachycardia                                          | 17            | 1.96 (1.49-2.34)    | 71            | 0.03 (0.01-0.06)      |
| Shock                                                | 17            | -                   | 71            | 0.02 (0.00-0.04)      |
| Gastrointestinal symptoms                            |               |                     |               |                       |
| Diarrhea                                             | 17            | 19.82 (18.47-21.17) | 71            | 18.52 (18.12-19.12)   |
| Abdominal pain                                       | 17            | 5.65 (4.87-6.43)    | 71            | 6.51 (6.19-6.82)      |
| Vomiting                                             | 17            | 9.30 (8.32-10.28)   | 71            | 5.00 (4.72-5.28)      |
| Nausea                                               | 17            | 13.16 (12.02-14.31) | 71            | 4.63 (4.36-4.90)      |
| Anorexia                                             | 17            | 24.07 (22.63-25.52) | 71            | 1.40 (1.25-1.56)      |
| Dehydration                                          | 17            | -                   | 71            | 0.03 (0.01-0.05)      |
| Neurological symptoms                                |               |                     |               |                       |
| Headache                                             | 17            | 44.40 (42.72-46.08) | 71            | 32.48 (31.88-33.08)   |
| Ageusia                                              | 17            | -                   | 71            | 1.89 (1.72-2.07)      |
| Dizziness                                            | 17            | 20.48 (19.11-21.84) | 71            | 0.37 (0.30-0.45)      |
| Symptom                                      | N. of patients | N. of studies | SARS-CoV % (95% CI) | SARS-CoV-2 % (95% CI) |
|----------------------------------------------|----------------|---------------|---------------------|----------------------|
| Anosmia                                      | 17             | 71            | 0.34 (0.26-0.41)    |                      |
| Impaired consciousness                       | 17             | 71            | 0.27 (0.20-0.33)    |                      |
| Agitation                                    | 17             | 71            | 0.17 (0.12-0.23)    |                      |
| Corticospinal tract signs                    | 17             | 71            | 0.17 (0.11-0.22)    |                      |
| Dysexecutive syndrome                        | 17             | 71            | 0.06 (0.03-0.09)    |                      |
| Perfusion abnormalities                      | 17             | 71            | 0.05 (0.02-0.08)    |                      |
| Acute cerebrovascular disease                | 17             | 71            | 0.04 (0.01-0.06)    |                      |
| Guillain-Barré syndrome (GBS)                | 17             | 71            | 0.03 (0.01-0.05)    |                      |
| Leptomeningeal enhancement                   | 17             | 71            | 0.03 (0.01-0.06)    |                      |
| Nerve pain                                   | 17             | 71            | 0.02 (0.00-0.04)    |                      |
| Seizure                                      | 17             | 71            | 0.01 (0.00-0.03)    |                      |
| Ataxia                                       | 17             | 71            | 0.004 (0.00-0.013)  |                      |
| Miller Fisher Syndrome                       | 17             | 71            | 0.004 (0.00-0.013)  |                      |
| Miller Fisher Syndrome                       | 17             | 71            | 0.004 (0.00-0.013)  |                      |
| Polyneuritis cranialis                       | 17             | 71            | 0.004 (0.00-0.013)  |                      |
| Anxiety                                      | 17             | 71            |                      | 0.15 (0.10-0.21)     |
| Kidney symptoms                              |                |               |                     |                      |
| Dialysis                                     | 17             | 71            | 0.11 (0.07-0.15)    |                      |
| Kidney injury                                | 17             | 71            | 0.11 (0.07-0.15)    |                      |
| Musculoskeletal and connective symptoms      |                |               |                     |                      |
| Myalgia/arthritis                            | 17             | 71            | 35.62 (35.00-36.23) |                      |
| Hypodynamia                                  | 17             | 71            | 0.25 (0.19-0.32)    |                      |
| Back discomfort                              | 17             | 71            | 0.01 (0.00-0.03)    |                      |
| Rigor                                        | 17             | 71            | 19.17 (17.84-20.50) |                      |
| Neck pain                                    | 17             | 71            | 0.09 (0.00-0.19)    |                      |
| Skin and subcutaneous tissue symptoms        |                |               |                     |                      |
| Itch                                         | 17             | 71            | 0.91 (0.79-1.04)    |                      |
| Maculopapular rash                           | 17             | 71            | 0.76 (0.64-0.87)    |                      |
| Urticaria                                    | 17             | 71            | 0.33 (0.25-0.40)    |                      |
| Pseudo-chilblains                            | 17             | 71            | 0.30 (0.23-0.38)    |                      |
| Chickenpox-like vesicles                     | 17             | 71            | 0.15 (0.10-0.20)    |                      |
| Pain                                         | 17             | 71            | 0.14 (0.09-0.19)    |                      |
| Livedo/necrosis                              | 17             | 71            | 0.09 (0.05-0.13)    |                      |
| Erythematous rash                            | 17             | 71            | 0.07 (0.04-0.25)    |                      |
| Burning                                      | 17             | 71            | 0.09 (0.06-0.13)    |                      |
| Urticaria                                    | 17             | 71            | 0.02 (0.00-0.04)    |                      |
| Cyanosis                                     | 17             | 71            | 0.004 (0.00-0.013)  |                      |
| Eye symptoms                                 |                |               |                     |                      |
| Conjunctival congestion                      | 17             | 71            | 0.05 (0.02-0.08)    |                      |
| Vision impairment                            | 17             | 71            | 0.01 (0.00-0.03)    |                      |
| Hepatic symptoms                             |                |               |                     |                      |
| Liver injury                                 | 17             | 71            | 0.37 (0.29-0.45)    |                      |

| Comorbidities and risk factor                |                |               |                     |                      |
| Characteristics                              | N. of studies  | SARS-CoV % (95% CI) | N. of studies  | SARS-CoV-2 % (95% CI) |
|----------------------------------------------|----------------|---------------------|----------------|----------------------|
| Patients, n.                                 | 17             | 3,365               | 72             | 26,650               |
| Gender                                       |                |                     |                |                      |
| Male, n. (%)                                 | 17             | 1,360 (40.4)        | 68             | 15,163 (58.3)        |
| Characteristics                                      | N. of studies | SARS-CoV-1 % (95% CI) | N. of studies | SARS-CoV-2 % (95% CI) |
|------------------------------------------------------|---------------|-----------------------|---------------|-----------------------|
| Patients, n.                                         | 17            | 3,365                 | 75            | 38,318                |
| Gender                                               |               |                       |               |                       |
| Male, n. (%)                                         | 17            | 1,360 (40.4)          | 71            | 15,532 (58.1)         |
| Female, n. (%)                                       | 17            | 2,005 (59.6)          | 71            | 11,215 (41.9)         |
| Prognosis                                            |               |                       |               |                       |
| Hospital admission                                   | 17            | 55.66 (53.98-57.34)*  | 73            | 91.60 (91.17-91.83)*  |
| Discharge                                            | 17            | 91.41 (90.46-92.36)*  | 65            | 52.53 (51.92-53.15)*  |
Diagnostic tests

The 2003 pandemic of SARS profiled the ability of modern diagnostic microbiology and molecular biology to identify, isolate and characterize, within weeks, a previously unknown virus. On 10 April 2003, quantitative TaqMan-format assay for SARS-associated coronavirus was published for the first time [51]. Diverse protocols were proposed within the different molecular testing approaches over time. Most conventional polymerase chain reaction (PCR) assays were designed with the Orf1b or nucleoprotein gene for nucleic acid amplification, and SYBR Green based PCR protocol was reported as a benefit to screen samples with sequence variations in the virus [52]. Also, monoclonal antibodies or monospecific polyclonal antibody directed to the nucleocapsid (N) protein were found to be a sensitive and specific test for antigen detection; however, most of these rapid tests have never been exhaustively investigated in prospective cohort studies owed to the short-lived epidemic [48].

Given the current epidemiology and the high risk of transmission, the rapid and accurate identification of the infection is crucial for effective COVID-19 containment. At writing time, real-time PCR molecular assays for detecting SARS-CoV-2 in respiratory specimens are the current reference standard for infection diagnosis. The technique is generally very sensitive and specific and may be used for routine diagnostics of COVID-19 [53]. However, Yong and colleagues showed the ineffectiveness of real-time PCR as the only diagnostic test due to its inability to detect previous infections highlighting the importance of using serological tests as well [54]. Where epidemiological information warns people might have been node of disease transmission, but they had recovered from sickness, SARS-CoV-2 IgG serology allows establishing past infection. In addition, if carried out within the correct timeframe after symptoms onset, serology assays can detect both active and past infections [55]. Remarkably, the importance of serological tests for epidemiological investigation of COVID-19 cases rapidly emerged in a much more pressing way than in SARS full epidemic happened. At the end of April 2003, tests to detect antibodies produced in response to the SARS coronavirus infection are under development but not still commercially available. ELISA (Enzyme Linked ImmunoSorbant Assay) test for the detection of IgM and IgG antibodies in serum produced positive results reliably after 21 from the onset of the disease and IFA (Immunofluorescence Assay) test for the detection of IgM produced positive results after about 10 days of illness [56].

Later studies revealed that specific serum antibodies against whole SARS-CoV by indirect immunofluorescence or neutralization tests starts to appear at about day 7 and, while IgM were not detectable after 2 to 3 months, IgG maintained for over one year [57].

The titer of neutralizing antibodies peaked from 20 to 30 days after infection and was sustained for a long time in those who survived, while the neutralizing antibody level of those who died peaked at day 14 and then gradually diminished [58].

In these months, a flood of novel rapid serologic immunoassays designs as long as point-of-care technologies are proposed, and a lot of them are commercially available. Despite the considerable role they play, some evidences suggest that many kits currently available are not adequately accurate [59] and several challenges remain, to which we must pay attention. Recognizing the disease, during the acute phase of infection, needs high sensitivity and specificity; cross-reactivity with other viral agents should be weighed; antibody kinetics over time must also be investigated, to determine thresholds of immunity [60]. Both these testings, molecular and serological, are expected to support welfare decision-makers about measures to contain the outbreak.

Prognosis

Of the 3,365 patients hospitalized for SARS-CoV and the 38,318 patients hospitalized for SARS-CoV-2 that were included in our analysis, 55.66% and 91.60%, respectively, were admitted to hospital. At the time the reports were written, 91.41% of patients hospitalized for SARS-CoV and only 52.53% of patients with SARS-CoV-2 were discharged.

Based on data from 17 studies on SARS and 72 studies on COVID-19, the percentage of deaths stood at 5.26% and 7.80% for SARS-CoV and SARS-CoV-2, respectively.

|       | Death       | 95% CI      |       |       |
|-------|-------------|-------------|-------|-------|
| SARS  | 17          | 5.26 (4.51-6.01)* | 72    | 7.80 (7.48-8.12)* |

* At the time of writing reports; for clinical features: 4 studies do not report gender differences, 1 study do not report age group; for comorbidities: 4 studies do not report gender differences; for prognosis: 2 studies do not report hospital admission, 10 studies do not report discharge, 3 studies do not report death.

Containment measures

During an unpredictable and unprecedented pandemic such as that caused by COVID-19, anxiety and stress – often boosted by the media as well as by the political decisions themselves – alter how people perceive new diseases and their consequent actions. Moreover, whenever decision-making involves risks, individuals can become irrational in several dysfunctional ways [61]. Consequently, the ideal approach to improve decision-making and crisis management should be reducing anxiety and stress through rapid diagnosis [62].
and specific antiviral treatments. However, in the real world, most countries are usually unprepared to face such a pandemic. In particular, during COVID-19, an initial lack of positive control, primers and/or probes as long as a lack of personnel/time and of specific therapies together with a large number of pauci-symptomatic and asymptomatic people yielded most policies to shift towards lockdown measures rather than modern laboratory-based testing and consequent quarantine [62, 63]. European countries, for instance, implemented a series of containment measures, ranging from lockdown to an intermediate safe distancing (Italy, France, Spain, Denmark, Norway, Switzerland, Austria, Belgium, UK and Germany), with only one country that has chosen not to adopt lockdown (Sweden) [64]. Most States in the world added in an unprecedented way lockdown measures to the other traditional containment measures adopted during the last epidemics, such as SARS [65]. However, this widespread governance resolution generated new research challenges. Currently, scientific and political institutions do not require any type of comparative study on the risks and benefits before implementing lockdown measures. This happens despite the consequences of these old measures to the overall mental and physical health of the population’s remain mostly unexplored [66].

Conclusions

COVID-19 and SARS are infections with similar phylogenetic and pathogenetic characteristics that primarily affect the respiratory and gastrointestinal systems. The knowledge acquired so far has allowed us to highlight some distinctive features of COVID-19 in comparison to SARS. SARS has a high prevalence of severe illness but with a low infectivity in the first days of illness, before the development of severe illness. Conversely, COVID-19 can be considered as a disease with a lower lethality rate but with high risk of transmission compared to SARS even in the presence of mild symptoms or in the absence of any visible signs of infection.

A rather high percentage of SARS patients had typical symptoms such as fever, cough, chills, headache, fatigue and myalgia. Among the most common symptoms in COVID-19 patients are cough, fever, myalgia, and headache, but there is no highly prevalent symptom such as fever that was detected in almost 90% of the SARS patients analyzed. Gastrointestinal and cardiovascular symptoms seem to be more common in SARS. Based on reports of more than 23,000 COVID-19 cases, numerous other less common and atypical manifestations including neurological symptoms (ageusia, anosmia), dermatologic manifestations and ocular symptoms, have also been identified. In light of this, the detection of fever, cough and shortness of breath as an identification method should be reviewed. In addition, COVID-19 patients exhibit a wide range of comorbidities. Therefore, it is very important to know what signs and symptoms to look out for and recognize and which diagnostic tests to use for prompt treatment and prevention of further infections. If clinical manifestations are mild and there is no need to seek medical care, it is very important that symptoms are monitored and national public health measures are followed in order to control the spread of the first epidemic wave in the countries where it is still in place or prevent a further wave of COVID-19.

Acknowledgements

Funding sources: this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest statement

The authors declare no conflict of interest.

Authors’ contributions

AZ reviewed the articles related to virological, epidemiological, and transmission aspects; VR investigated the containment strategies; AA examined the diagnostic laboratory tests; MG carried out the analysis of data on clinical features and comorbidities. All authors contributed to the preparation of the manuscript related to their sections and approved the final version to be submitted.

References

[1] WHO. Coronavirus disease (COVID-19) Situation Report - 157. Geneva, Switzerland: World Health Organization 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200625-covid-19-sitrep-157.pdf?sfvrsn=423f4a82_2 (accessed on 26 June 2020).
[2] Najafimehr H, Mohamed Ali K, Safari S, Yousefifard M, Hosseini M. Estimation of basic reproduction number for COVID-19 and the reasons for its differences. Int J Clin Pract 2020;74:e13518. https://doi.org/10.1111/ijcp.13518
[3] WHO. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). Geneva, Switzerland: World Health Organization 2003. https://apps.who.int/iris/handle/10665/70863 (accessed on 16 June 2020).
[4] Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammandi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemiics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 2020;49:717-26. https://doi.org/10.1093/ije/dya033
[5] Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42. https://doi.org/10.1001/jama.2020.2648
[6] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong
S. Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu YJ, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. https://doi.org/10.1183/13993003.00547-2020

[7] Chan-Yeung M. Xu RH. SARS: epidemiology. Respirology 2003;8:S9-514. https://doi.org/10.1046/j.1440-1843.2003.00518.x

[8] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74. https://doi.org/10.1016/S0140-6736(20)30251-8

[9] Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Kathtra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Ginn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailis DE, Stott JM, Yang GS, Plummer F, Aartsen H, Arztsoh B, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebout M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabana A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunnham RK, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. The Genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-404. https://doi.org/10.1126/science.1085953

[10] Sah R, Rodriguez-Morales AJ, Hla R, Chu DKW, Gu H, Peiris M, Bastolla A, Lal BK, Ojha HC, Rabaan AA, Zambrano LI, Costello A, Moritz K, Pandey BD, Poon LLM. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepa. Microbiol Resour Announc 2020;9:e00169-20. https://doi.org/10.1128/MRA.00169-20

[11] Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, Boerwinkel E, Fu YX. Moderate mutation rate in the SARS coronavirus genome and its implications. BMC Evol Biol 2004;4:21. https://doi.org/10.1186/1471-2148-4-21

[12] Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2. J Med Virol 2020;92:675-9. https://doi.org/10.1002/jmv.25723

[13] Guangdong Public Health Office. 2003: Document No 2. Summary report of investigating an atypical pneumonia outbreak in Zhongshan. 2003.

[14] WHO. Update 95 - SARS: Chronology of a serial killer. Geneva, Switzerland: World Health Organization 2003. https://www.who.int/csr/sars/country/jrhv2003_07_04/en

[15] WHO. First data on stability and resistance of SARS coronavirus completed by members of WHP laboratory network. Geneva, Switzerland: World Health Organization 2003. https://www.who.int/csr/sars/country/jrv2003_09_23/en (accessed 02 June 2020).

[16] Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City. Wuhan: China Wuhan Municipal Health Commission. http://wjw.wuhan.gov.cn/front/web/showDetail/2019121308989 (accessed 02 June 2020).

[17] Wu P, Duan F, Luo C, Liu Q, Xu Q, Liang L, Wu K. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei province, China. JAMA Ophthalmol 2020;138:575-8. https://doi.org/10.1001/jamaophthalmology.2020.1291

[18] Mclntosh K. Coronavirus: a comparative review. Curr Top Microbiol 1974;63:85-129.

[19] Chen Y, Chen L, Deng Q, Zhang G, Wu K, Li N, Yang L, Liu B, Wang W, Wei C, Yang J, Ye G, Cheng Z. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol 2020;92:833-40. https://doi.org/10.1002/jmv.25825

[20] Cheung KS, Hung IFN, Chan PPy, Lung KC, Tso E, Liu R, Ng YY, Chu MY, Chung TWH, Tam AR, Yip CCY, Leung KH, Fung AY, Zhang RR, Lin Y, Cheng HM, Zhang AJX, To KKW, Chan KH, Yuen KY, Leung WK. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and meta-analysis. Gastroenterology 2020;159(1). https://doi.org/10.1053/j. gastro.2020.03.065

[21] Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shet CC, Ng PC, Lam PW, Ho IC, To WW, Lai ST, Yan WW, Tan PY. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004;191:292-7. https://doi.org/10.1016/j.ajog.2003.11.019

[22] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intratracheal viral transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395:809-15. https://doi.org/10.1016/S0140-6736(20)30360-3

[23] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ, Andersen KG. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564-7. https://doi.org/10.1056/NEJMoa2004793

[24] WHO. First data on stability and resistance of SARS coronavirus completed by members of WHP laboratory network. Geneva, Switzerland: World Health Organization 2003. https://www.who.int/csr/sars/survival_2003_05_04/en (accessed 09 June 2020).

[25] European Centre for Disease Prevention and Control. Interim guidance for environmental cleaning in non-healthcare facilities exposed to 2019-nCoV. Stockholm: ECDC 2020. https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-guidance-environmental-cleaning-non-healthcare-facilities.pdf (accessed 12 June 2020).

[26] Wilder-Smith A, Telemar MD, Heng BH, Earnest A, Ling AE,
Clinical Features of COVID-19 and SARS Epidemics

Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007;20:660-94. https://doi.org/10.1128/CMR.00023-07

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020;323:2052-9. https://doi.org/10.1001/jama.2020.6775

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu Y, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng F, Wang PM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. https://doi.org/10.1056/NEJMoa200232

Drosten C, Günther S, Preisler W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burgtuère AM, Cinaid J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vehrs S, Klenk HD, Osterhaus AD, Schmitz H, Dorr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76. https://doi.org/10.1056/NEJMoa030747

Poon LL, Chan KH, Wong OK, Yam WC, Yuen KY, Guan Y, Lo YM, Peiris JS. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003;28:233-8. https://doi.org/10.1016/S1043-4666(03)00088-2

van Kasteren PB, van der Beek B, van den Brink S, Wijmken L, de Jonge J, van den Brandt A, Molenkamp R, Reusken CBEM, Meijer A. Comparison of seven commercial RT-PCR diagnostic kits for SARS-CoV-2. J Clin Virol 2020;128:104412. https://doi.org/10.1016/j.jcv.2020.104412

Yong SEF, Anderson DE, Wei PE, Pang J, Chia WN, Tan CW, Teoh YL, Rajendram P, Toh MPHS, Poh C, Koh VTI, Lum J, Suhaimi NM, Chia PY, Chen MI, Vasos S, Ong B, Leo YM, Wang L, Lee VJM. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect Dis 2020;20:809-15. https://doi.org/10.1016/S1473-3099(20)30273-5

Luo B, Li TD, Zheng SF, Su YQ, Li ZY, Liu W, Yu F, Ge SX, Zou QD, Yuan Q, Liu S, Hong CM, Yao XY, Zhang XJ, Wu DH, Zhou GL, Hou WH, Li TT, Zhang YL, Zhang SY, Fan J, Zhang J, Xia NS, Chen Y. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J 2020;2000763. https://doi.org/10.1183/13993003.00763-2020

WHO. Severe Acute Respiratory Syndrome (SARS): Laboratory diagnostic tests. Geneva, Switzerland: World Health Organization 2003. https://www.who.int/health-topics/severe-acute-respiratory-syndrome-laboratory-diagnostic-tests

Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsio HW, Huang Y, Peiris JS, Yuen KY. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol 2004;11:665-8. https://doi.org/10.1128/CDLII.11.665-668.2004

Zhang L, Zhang F, Yu W, He T, Yu J, Ye CI, Ba L, Li W, Farzana M, Chen Z, Yuen KY, Ho D. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol 2006;78:1-8. https://doi.org/10.1002/jmv.20499

Cassandri I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, Bruno R, Mojoli F, Baldanti F, Members of the San Matteo Pavia. COVID-19 Task Force. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol 2020;92:1724-7. https://doi.org/10.1002/jmv.25800
[60] Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis 2020;20:758-9. https://doi.org/10.1016/S1473-3099(20)30322-4
[61] Kahneman D, Tversky A. Choices, values, and frames. Am Psychol 1984;39:341-50.
[62] Lagier JC, Colson P, Tissot Dupont H, Salomon J, Doudier B, Aubry C, Gouriet F, Baron S, Dudoet P, Flores R, Ailhaud L, Gautret P, Parola P, La Scolla B, Raoult D, Brouqui P. Testing the repatriated for SARS-CoV-2: should laboratory-based quarantine replace traditional quarantine? Travel Med Infect Dis 2020;34:101624. https://doi.org/10.1016/j.tmrid.2020.101624
[63] Reusken CBEM, Broberg EK, Haagmans B, Meijer A, Corman VM, Papa A, Charrel R, Drosten C, Koopmans M, Leitmeyer K, On Behalf Of Evd-LabNet And Erli-Net. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Euro Surveill 2020;25:200008. https://doi.org/10.2807/1560-7917.ES.2020.25.6.200008
[64] Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, Whittaker C, Zhu H, Berah T, Eaton JW, Monod M; Imperial College COVID-19 Response Team, Ghani AC, Donnelly CA, Riley SM, Vollmer MAC, Ferguson NM, Okell LC, Bhatt S. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020;584:257-61. https://doi.org/10.1038/s41586-020-2405-7
[65] Qualls N, Levitt A, Kanade N, Wright-Jegede N, Dopson S, Biggstaff M, Reed C, Uzicanin A; CDC Community Mitigation Guidelines Work Group. Community mitigation guidelines to prevent pandemic influenza - United States, 2017. MMWR Recomm Rep 2017;66:1-34. https://doi.org/10.15585/mmwr.rr6601a1
[66] Mackolil J, Mackolil J. Addressing psychosocial problems associated with the COVID-19 lockdown. Asian J Psychiatr 2020;51:102156. https://doi.org/10.1016/j.ajp.2020.102156

Received on July 15, 2020. Accepted on February 3, 2021.

Correspondence: Antonella Zizza, National Research Council, Institute of Clinical Physiology, Campus Ecotekne, via Monteroni, Lecce, Italy - E-mail: zizza@ifc.cnr.it

How to cite this article: Zizza A, Recchia V, Aloisi A, Guido M. Clinical features of COVID-19 and SARS epidemics. A literature review. J Prev Med Hyg 2021;62:E13-E24. https://doi.org/10.15167/2421-4248/jpmh2021.62.1.1680

© Copyright by Pacini Editore Srl, Pisa, Italy

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en